Top 20 of Lung Neoplasms

Article title # Publications/# Citations

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

2005: BLEbert; MAGillette; TRGolub; ESLander; JPMesirov; VKMootha; SMukherjee; APaulovich; ... SLPomeroy; ASubramanian; PTamayo;

3414

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

2004: DWBell; BWBrannigan; DCChristiani; SGurubhagavatula; DAHaber; FGHaluska; PLHarris; SMHaserlat; ... DNLouis; TJLynch; RAOkimoto; JSettleman; RSordella; JGSupko;

1246

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

2004: TJBoggon; MJEck; YFujii; SGabriel; HGreulich; PHerman; PAJänne; BEJohnson; ... FJKaye; JCLee; NLindeman; MMeyerson; KNaoki; JGPaez; HSasaki; WRSellers; STracy;

1114

Operating characteristics of a rank correlation test for publication bias.

1994: CBBegg; MMazumdar;

860

ras oncogenes in human cancer: a review.

1989: JLBos;

741

RAS is regulated by the let-7 microRNA family.

2005: DBrown; MByrom; ACheng; HGrosshans; RJarvis; SMJohnson; ELabourier; KLReinert; JShingara; FJSlack;

732

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

2004: CCôme; JLDonaher; IGitelman; RAItzykson; SAMani; SRamaswamy; ARichardson; PSavagner; RAWeinberg; JYang;

661

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

2007: LCCantley; FCappuzzo; JChristensen; JAEngelman; CMGale; AJHolmes; CHyland; PAJänne; ... BEJohnson; TKosaka; CLee; NLindeman; TMitsudomi; TMok; JOPark; AMRogers; YSong; KZejnullahu; XZhao;

646

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

2006: JBrahmer; ADowlati; RGray; DHJohnson; RLilenbaum; MCPerry; ASandler; JHSchiller;

646

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

1993: NKAaronson; SAhmedzai; BBergman; MBullinger; ACull; JCde Haes; NJDuez; AFiliberti; HFlechtner; SBFleishman;

618

High frequency of mutations of the PIK3CA gene in human cancers.

2004: ABardelli; AGazdar; KWKinzler; SMarkowitz; SMPowell; JPtak; GJRiggins; YSamuels; ... NSilliman; SSzabo; VEVelculescu; BVogelstein; ZWang; JKWillson; HYan;

594

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

2004: JDoherty; LFulton; RHeelan; MKris; DKupfer; EMardis; VMiller; WPao; ... KPoliti; VRusch; ISarkaria; BSingh; HVarmus; RWilson; MZakowski;

590

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

2006: EBowman; GACalin; NCaplen; CMCroce; CCHarris; KKumamoto; CGLiu; AOkamoto; ... MSeike; RMStephens; TTanaka; NYanaihara; MYi; JYokota;

554

Genes that mediate breast cancer metastasis to lung.

2005: PDBos; WLGerald; DDGiri; GPGupta; JMassagué; AJMinn; ABOlshen; WShu; PMSiegel; AViale;

551

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

2009: AAArmour; BChewaskulyong; DTChu; ELDuffield; MFukuoka; BHan; YIchinose; HJiang; ... BMargono; TSMok; YNishiwaki; YOhe; NSaijo; PSunpaweravong; SThongprasert; CLWatkins; YLWu; CHYang; JJYang;

549

Somatic mutations affect key pathways in lung adenocarcinoma.

2008: RAbbott; JBaldwin; DGBeer; SBroderick; ACChang; KChen; LRChirieac; KCibulskis; ... KClerc; SDCrosby; LDing; DJDooling; BHDunford-Shore; ADutt; TFennell; GFewell; LFulton; RSFulton; SBGabriel; GGetz; RAGibbs; TGiordano; MLGonzalez-Garay; PJGood; HGreulich; CHaipek; OHall; MHanna; ACHawes; SNJhangiani; BEJohnson; DCKoboldt; AKraja; MLadanyi; ESLander; DELarson; MSLawrence; LRLewis; LLin; ERMardis; TMathew; MDMcLellan; GAMetcalf; RMeyer; MMeyerson; AMilosavljevic; TLMiner; MBMorgan; DMMuzny; BNg; RCOnofrio; MBOrringer; JROsborne; BOzenberger; WPao; CPohl; MAProvince; YRen; JRobinson; JARoth; ASabo; SSander; CSSawyer; SEScherer; HSchmidt; HShen; XShi; CSougnez; MRSpitz; YTang; RKThomas; GTonon; WDTravis; HEVarmus; TVickery; MAWatson; GMWeinstock; BAWeir; MCWendl; DAWheeler; RKWilson; WWinckler; IIWistuba; JYao; AYoshizawa; QZhang; XZhao; YZhu; LZiaugra; MCZody;

546

Erlotinib in previously treated non-small-cell lung cancer.

2005: National Cancer Institute of Canada Clinical Trials Group; ABezjak; DCampos; TCiuleanu; GClark; MDediu; BFindlay; VHirsh; ... DJohnston; SMaoleekoonpiroj; RMartins; JRodrigues Pereira; PSantabarbara; LSeymour; FAShepherd; MSmylie; EHTan; SThongprasert; DTu; Mvan Kooten;

536

Oncogenic pathway signatures in human cancers as a guide to targeted therapies.

2005: ABerchuck; AHBild; JTChang; DChasse; HKDressman; DHarpole; MBJoshi; JMLancaster; ... JRMarks; JRNevins; JAOlson; APotti; QWang; MWest; GYao;

517

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

2007: LMa; JTeruya-Feldstein; RAWeinberg;

495

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

2005: MGKris; VAMiller; WPao; KAPoliti; GJRiely; RSomwar; HVarmus; MFZakowski;

484